Medicine information JETREA 0.5mg / 0.2ml concentrate for solution for injection

Product code:
W60446001
Quantity:
1
Indicated for:
vitreomacular traction
Route of administration:
injectable
Substance:
ocriplasmin (enzyme)
ATC
S01XA22 — Sensory organs | Other ophthalmologicals
Ocriplasmin is an enzyme used in the treatment of symptomatic vitreomacular adhesion, an eye condition that can affect vision. It works by dissolving proteins that bind the vitreous body to the retina, reducing traction.

The medication is administered via intravitreal injection, as directed by an ophthalmologist. It is important for patients to follow the doctor's recommendations and undergo regular check-ups to monitor treatment progress.

Patients should be aware of potential side effects, such as eye pain, blurred vision, or increased intraocular pressure. It is important to inform the doctor of any unusual symptoms.

Common side effects include eye pain, blurred vision, and increased intraocular pressure. In rare cases, severe reactions such as retinal detachment or eye infections may occur. Patients should be informed of these risks before use.

General data about JETREA 0.5mg / 0.2ml

Substance:
ocriplasmin
Date of latest medicines list:
01-04-2014
Product code:
W60446001
Strength:
0.5mg / 0.2ml
Pharmaceutical form:
concentrate for solution for injection
Quantity:
1
Product type:
Original
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
THROMBOGENICS NV - BELGIA
Holder:
THROMBOGENICS NV - BELGIA
Number:
819/2013/01
Shelf life:
18 months

Official documents

The SmPC text is not displayed because a match to this medicine, strength and pharmaceutical form has not been confirmed.

Added to database:
18/04/2013
Source record updated:
19/06/2025